Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

Cholangiocarcinoma Clinical Trial

Official title:

Evaluating Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements for Oncologic Patients - A Cross-Sectional Survey Study at Norris Comprehensive Cancer Center

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03563352
• Other study ID #: 0S-17-4
• Secondary ID: NCI-2018-009480S
• Status: Withdrawn
• Start date: August 30, 2018
• Est. completion date: September 24, 2020

Study information

• Verified date: December 2020
• Source: University of Southern California
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer. Learning what participants like and dislike about their current or past used nutritional supplements may help doctor know how to improve them.

Description:

PRIMARY OBJECTIVES:

I. Identify how patients with cancer are obtaining nutrition to support medical management.

SECONDARY OBJECTIVES:

I. Examine associations of gastrointestinal side effects with specific diagnoses and respective medical therapies.

II. Understand how patients access information regarding nutritional supplements.

III. Evaluate patient satisfaction with currently available oral nutritional supplements (ONS).

IV. Identify patient preferences in formulating a novel nutritional supplement.

OUTLINE:

Participants attend an interview over 15 minutes and complete surveys.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 24, 2020
• Est. primary completion date: September 24, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability to comprehend English (both reading and writing)

• Subjects in the inpatient and outpatient setting with the diagnosis of breast cancer, colorectal cancer, upper gastrointestinal cancer (including gastric, pancreatic, and cholangiocarcinoma), or prostate cancer

• Receiving chemotherapy, biologic, or hormonal therapy in the University of Southern California (USC) Norris Comprehensive Cancer Center Day Hospital

• Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

• Patients with a mental disability that makes them unable to understand and respond to the questions

• Patients with reported non-oncologic associated deficits in taste and smell

Related Conditions & MeSH terms

• Breast Carcinoma
• Breast Neoplasms
• Carcinoma
• Cholangiocarcinoma
• Colorectal Carcinoma
• Colorectal Neoplasms
• Digestive System Neoplasms
• Gastric Carcinoma
• Gastrointestinal Neoplasms
• Malignant Digestive System Neoplasm
• Pancreatic Carcinoma
• Pancreatic Neoplasms
• Prostate Carcinoma
• Stomach Neoplasms

Intervention

Other:
• Interview
Attend an interview
• Survey Administration
Ancillary studies

Locations

Country	Name	City	State
United States	USC / Norris Comprehensive Cancer Center	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of Southern California	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The way patients with cancer choose and obtain nutritional supplements to support medical management	Data from the oral nutritional supplement survey that examines quality, quantity, access and affordability of oral nutrional supplements will be summarized.	Up to 1 year
Secondary	Associations of gastrointestinal side effects with specific diagnoses and respective medical therapies	Data from the survey will be used for testing the association of gastrointestinal side effects with specific diagnosis and medical therapies.	Up to 1 year